A review of medical treatments of cerebral vasospasm

Neurological Research

Volumn 30, Issue 5, 2008, Pages 444-449

  Otten, Marc L ^a   Mocco, J ^a   Connolly Jr , E Sander ^a   Solomon, Robert A ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

Aneurysmal subarachnoid hemorrhage; Cerebral vasospasm

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CD11 ANTIGEN; CD18 ANTIGEN; CLAZOSENTAN; CYCLOSPORIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAGNESIUM SULFATE; METHYLPREDNISOLONE; NAFAMSTAT MESILATE; NICARDIPINE; NIMODIPINE; NITRIC OXIDE; PRAVASTATIN; SERINE PROTEINASE INHIBITOR; SIMVASTATIN;

ARTERY STEAL SYNDROME; BRAIN ARTERY ANEURYSM; BRAIN INFARCTION; BRAIN VASOSPASM; CLINICAL TRIAL; DRUG COST; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HEMODILUTION; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; INTRACRANIAL PRESSURE; NONHUMAN; PROPHYLAXIS; REVIEW; SIDE EFFECT; SUBARACHNOID HEMORRHAGE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CALCIUM CHANNEL BLOCKERS; ENZYME INHIBITORS; HUMANS; SUBARACHNOID HEMORRHAGE; VASODILATOR AGENTS; VASOSPASM, INTRACRANIAL;

EID: 47549098000     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/174313208X284089     Document Type: Review

References (85)

1. van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: Diagnosis, causes and management. Brain 2001; 124: 249-278
2. Hop JW, Rinkel GJ, Algra A, et al. Case-fatality rates and functional outcome after subarachnoid hemorrhage: A systematic review. Stroke 1997; 28: 660-664
3. Broderick JP, Brott TG, Duldner JE, et al. Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke 1994; 25: 1342-1347
4. Mocco J, Zacharia BE, Komotar RJ, et al. A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurosurg Focus 2006; 21: E9
5. Biller J, Godersky JC, Adams HP, Jr. Management of aneurysmal subarachnoid hemorrhage. Stroke 1988; 19: 1300-1305
6. Treggiari-Venzi MM, Suter PM, Romand JA. Review of medical prevention of vasospasm after aneurysmal subarachnoid hemorrhage: A problem of neurointensive care. Neurosurgery 2001; 48: 249-261
7. Tettenborn D, Dycka J. Prevention and treatment of delayed ischemic dysfunction in patients with aneurysmal subarachnoid hemorrhage. Stroke 1990; 21: IV85-IV89
8. Tettenborn D, Dycka J, Volberg E, et al. Blood pressure and heart rate during treatment with nimodipine in patients with subar-achnoid hemorrhage. Neurochirurgia (Stuttg) 1985; 28 (Suppl. 1): S84-S86
9. Barker FG 2nd, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: A metaanalysis. J Neurosurg 1996; 84: 405-414
10. Murray GD. Surgical bleeding and calcium antagonists. British aneurysm nimodipine trial reported improved clinical outcome with nimodipine. BMJ 1995; 311: 388-389
11. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989; 298: 636-642
12. Karinen P, Koivukangas P, Ohinmaa A, et al. Cost-effectiveness analysis of nimodipine treatment after aneurysmal subarachnoid hemorrhage and surgery. Neurosurgery 1999; 45: 780-784
13. Flamm ES, Adams HP, Jr, Beck DW, et al. Dose-escalation study of intravenous nicardipine in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 1988; 68: 393-400
14. Haley EC, Jr, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal sub-arachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 1993; 78: 537-547
15. Haley EC, Jr, Kassell NF, Torner JC. A randomized trial of nicardipine in subarachnoid hemorrhage: Angiographic and transcranial Doppler ultrasound results. A report of the Cooperative Aneurysm Study. J Neurosurg 1993; 78: 548-553
16. Haley EC, Jr, Kassell NF, Torner JC, et al. A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 1994; 80: 788-796
17. Kassell NF, Helm G, Simmons N, et al. Treatment of cerebral vasospasm with intra-arterial papaverine. J Neurosurg 1992; 77: 848-852
18. Egge A, Waterloo K, Sjoholm H, et al. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: A clinical, prospective, randomized, controlled study. Neurosurgery 2001; 49: 593-605
19. Sen J, Belli A, Albon H, et al. Triple-H therapy in the management of aneurysmal subarachnoid haemorrhage. Lancet Neurol 2003; 2: 614-621
20. Solenski NJ, Haley EC, Jr, Kassell NF, et al. Medical complications of aneurysmal subarachnoid hemorrhage: A report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med 1995; 23: 1007-1017
21. Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: A randomized controlled trial. Stroke 2000; 31: 383-391
22. Macdonald RL, Curry DJ, Aihara Y, et al. Magnesium and experimental vasospasm. J Neurosurg 2004; 100: 106-110
23. Veyna RS, Seyfried D, Burke DG, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002; 96: 510-514
24. van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: A randomized controlled trial. Stroke 2005; 36: 1011-1015
25. Prevedello DM, Cordeiro JG, de Morais AL, et al. Magnesium sulfate: Role as possible attenuating factor in vasospasm morbidity. Surg Neurol 2006; 65 (Suppl. 1): S1:14-S1:20
26. Thomas JE, Nemirovsky A, Zelman V, et al. Rapid reversal of endothelin-1-induced cerebral vasoconstriction by intrathecal administration of nitric oxide donors. Neurosurgery 1997; 40: 1245-1249
27. Hirsh LF. Intra-arterial nitroprusside treatment of acute experimental vasospasm. Stroke 1980; 11: 601-605
28. Tierney TS, Clatterbuck RE, Lawson C, et al. Prevention and reversal of experimental posthemorrhagic vasospasm by the periadventitial administration of nitric oxide from a controlled-release polymer. Neurosurgery 2001; 49: 945-951
29. Andaluz N, Zuccarello M. Fenestration of the lamina terminalis as a valuable adjunct in aneurysm surgery. Neurosurgery 2004; 55: 1050-1059
30. Kaynar MY, Tanriverdi T, Kafadar AM, et al. Detection of soluble intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in both cerebrospinal fluid and serum of patients after aneurysmal subarachnoid hemorrhage. J Neurosurg 2004; 101: 1030-1036
31. Rothoerl RD, Schebesch KM, Kubitza M, et al. ICAM-1 and VCAM-1 expression following aneurysmal subarachnoid hemorrhage and their possible role in the pathophysiology of subsequent ischemic deficits. Cerebrovasc Dis 2006; 22: 143-149
32. Clatterbuck RE, Oshiro EM, Hoffman PA, et al. Inhibition of vasospasm with lymphocyte function-associated antigen-1 monoclonal antibody in a femoral artery model in rats. J Neurosurg 2002; 97: 676-682
33. Pradilla G, Wang PP, Legnani FG, et al. Prevention of vasospasm by anti-CD11/CD18 monoclonal antibody therapy following subarachnoid hemorrhage in rabbits. J Neurosurg 2004; 101: 88-92
34. Sercombe R, Dinh YR, Gomis P. Cerebrovascular inflammation following subarachnoid hemorrhage. Jpn J Pharmacol 2002; 88: 227-249
35. Bavbek M, Polin R, Kwan AL, et al. Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Stroke 1998; 29: 1930-1935
36. Clatterbuck RE, Gailloud P, Ogata L, et al. Prevention of cerebral vasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg 2003; 99: 376-382
37. Oshiro EM, Hoffman PA, Dietsch GN, et al. Inhibition of experimental vasospasm with anti-intercellular adhesion mole-cule-1 monoclonal antibody in rats. Stroke 1997; 28: 2031-2037
38. Roux S, Breu V, Giller T, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997; 283: 1110-1118
39. Frazier JL, Pradilla G, Wang PP, et al. Inhibition of cerebral vasospasm by intracranial delivery of ibuprofen from a controlled-release polymer in a rabbit model of subarachnoid hemorrhage. J Neurosurg 2004; 101: 93-98
40. Elkind MS, Flint AC, Sciacca RR, et al. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 2005; 65: 253-258
41. Adams HP, Jr, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994; 25: 1901-1914
42. Khajavi K, Ayzman I, Shearer D, et al. Prevention of chronic cerebral vasospasm in dogs with milrinone. Neurosurgery 1997; 40: 354-362
43. Manno EM, Gress DR, Ogilvy CS, et al. The safety and efficacy of cyclosporine A in the prevention of vasospasm in patients with Fisher grade 3 subarachnoid hemorrhages: A pilot study. Neurosurgery 1997; 40: 289-293
44. Provencio JJ, Vora N. Subarachnoid hemorrhage and inflammation: Bench to bedside and back. Semin Neurol 2005; 25: 435-444
45. Anggard E. Nitric oxide: Mediator, murderer, and medicine. Lancet 1994; 343: 1199-1206
46. Faraci FM. Role of nitric oxide in regulation of basilar artery tone in vivo. Am J Physiol 1990; 259: H1216-H1221
47. Gabikian P, Clatterbuck RE, Eberhart CG, et al. Prevention of experimental cerebral vasospasm by intracranial delivery of a nitric oxide donor from a controlled-release polymer: Toxicity and efficacy studies in rabbits and rats. Stroke 2002; 33: 2681-2686
48. Jung CS, Iuliano BA, Harvey-White J, et al. Association between cerebrospinal fluid levels of asymmetric dimethyl-L-arginine, an endogenous inhibitor of endothelial nitric oxide synthase, and cerebral vasospasm in a primate model of subarachnoid hemorrhage. J Neurosurg 2004; 101: 836-842
49. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu Rev Pharmacol Toxicol 1990; 30: 535-560
50. Pluta RM, Dejam A, Grimes G, et al. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA 2005; 293: 1477-1484
51. Hino A, Tokuyama Y, Weir B, et al. Changes in endothelial nitric oxide synthase mRNA during vasospasm after subarachnoid hemorrhage in monkeys. Neurosurgery 1996; 39: 562-567
52. Pluta RM, Oldfield EH, Boock RJ. Reversal and prevention of cerebral vasospasm by intracarotid infusions of nitric oxide donors in a primate model of subarachnoid hemorrhage. J Neurosurg 1997; 87: 746-751
53. Pluta RM, Thompson BG, Dawson TM, et al. Loss of nitric oxide synthase immunoreactivity in cerebral vasospasm. J Neurosurg 1996; 84: 648-654
54. Thomas JE, Rosenwasser RH. Reversal of severe cerebral vasos-pasm in three patients after aneurysmal subarachnoid hemorrhage: Initial observations regarding the use of intraventricular sodium nitroprusside in humans. Neurosurgery 1999; 44: 48-57
55. Thomas JE, Rosenwasser RH, Armonda RA, et al. Safety of intrathecal sodium nitroprusside for the treatment and prevention of refractory cerebral vasospasm and ischemia in humans. Stroke 1999; 30: 1409-1416
56. Afshar JK, Pluta RM, Boock RJ, et al. Effect of intracarotid nitric oxide on primate cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 1995; 83: 118-122
57. Dietrich HH, Dacey RG, Jr. Molecular keys to the problems of cerebral vasospasm. Neurosurgery 2000; 46: 517-530
58. Macdonald RL, Weir BK. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 1991; 22: 971-982
59. Heros RC, Zervas NT, Lavyne MH, et al. Reversal of experimental cerebral vasospasm by intravenous nitroprusside therapy. Surg Neurol 1976; 6: 227-229
60. Pradilla G, Thai QA, Legnani FG, et al. Delayed intracranial delivery of a nitric oxide donor from a controlled-release polymer prevents experimental cerebral vasospasm in rabbits. Neurosurgery 2004; 55: 1393-1399
61. Egemen N, Turker RK, Sanlidilek U, et al. The effect of intrathecal sodium nitroprusside on severe chronic vasospasm. Neurol Res 1993; 15: 310-315
62. Kistler JP, Lees RS, Candia G, et al. Intravenous nitroglycerin in experimental cerebral vasospasm. A preliminary report. Stroke 1979; 10: 26-29
63. Asano T. Oxyhemoglobin as the principal cause of cerebral vasospasm: A holistic view of its actions. Crit Rev Neurosurg 1999; 9: 303-318
64. Ito Y, Isotani E, Mizuno Y, et al. Effective improvement of the cerebral vasospasm after subarachnoid hemorrhage with low-dose nitroglycerin. J Cardiovasc Pharmacol 2000; 35: 45-50
65. Paulson OB. Regional cerebral blood flow in apoplexy due to occlusion of the middle cerebral artery. Neurology 1970; 20: 63-77
66. Raabe A, Zimmermann M, Setzer M, et al. Effect of intraventricular sodium nitroprusside on cerebral hemodynamics and oxygenation in poor-grade aneurysm patients with severe, medically refractory vasospasm. Neurosurgery 2002; 50: 1006-1013
67. Vajkoczy P, Horn P, Bauhuf C, et al. Effect of intra-arterial papaverine on regional cerebral blood flow in hemodynamically relevant cerebral vasospasm. Stroke 2001; 32: 498-505
68. Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003; 9: 1498-1505
69. Hansen-Schwartz J, Nordstrom CH, Edvinsson L. Human endothelin subtype A receptor enhancement during tissue culture via de novo transcription. Neurosurgery 2002; 50: 127-133
70. Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg 2000; 92: 390-400
71. Juvela S. Plasma endothelin and big endothelin concentrations and serum endothelin-converting enzyme activity following aneurysmal subarachnoid hemorrhage. J Neurosurg 2002; 97: 1287-1293
72. Schilling L, Vatter H, Mursch K, et al. Characterization of the contractile and relaxant action of the endothelin-1 precursor, big endothelin-1, in the isolated rat basilar artery. Peptides 2000; 21: 91-99
73. Suzuki K, Meguro K, Sakurai T, et al. Endothelin-1 concentration increases in the cerebrospinal fluid in cerebral vasospasm caused by subarachnoid hemorrhage. Surg Neurol 2000; 53: 131-135
74. Nilsson T, Cantera L, Adner M, et al. Presence of contractile endothelin-A and dilatory endothelin-B receptors in human cerebral arteries. Neurosurgery 1997; 40: 346-351
75. Edwards DH, Byrne JV, Griffith TM. The effect of chronic subarachnoid hemorrhage on basal endothelium-derived relaxing factor activity in intrathecal cerebral arteries. J Neurosurg 1992; 76: 830-837
76. Sakowitz OW, Wolfrum S, Sarrafzadeh AS, et al. Relation of cerebral energy metabolism and extracellular nitrite and nitrate concentrations in patients after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 2001; 21: 1067-1076
77. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725-31729
78. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-1131
79. McGirt MJ, Lynch JR, Parra A, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 2002; 33: 2950-2956
80. Parra A, Kreiter KT, Williams S, et al. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: A matched controlled cohort study. Neurosurgery 2005; 56: 476-484
81. Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: A phase II randomized placebo-controlled trial. Stroke 2005; 36: 1627-1632
82. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: Results of a pilot randomized clinical trial. Stroke 2005; 36: 2024-2026
83. Haley EC, Jr, Kassell NF, Alves WM, et al. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 1995; 82: 786-790
84. Haley EC, Jr, Kassell NF, Apperson-Hansen C, et al. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in North America. J Neurosurg 1997; 86: 467-474
85. Morizane A, Nakahara I, Sakai N, et al. [Endovascular surgery for untreated ruptured aneurysm with symptomatic vasospasm]. No Shinkei Geka 1999; 27: 941-946